D. Gary Gilliland

25.7k citations

126 papers · 16.2k indexed · 10 hit papers · h-index 62

Molecular Biology top 0.5%
Hematology top 0.02%
Genetics top 0.05%
Oncology top 0.5%
Public Health, Environmental and Occupational Health top 0.5%

Co-authors: Todd R. Golub Brian J.P. Huntly George F. Barker Michael Lovett Louise Kelly Nancy A. Speck Zuzana Tóthová Ayalew Tefferi
Topics: Acute Myeloid Leukemia Research (48 papers)Chronic Myeloid Leukemia Treatments (47 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (25 papers)
Cited by: Hematology Genetics Rheumatology
Journals: Nature New England Journal of Medicine Cell
Partner nations: United States Germany France

In The Last Decade

D. Gary Gilliland

126 papers receiving 15.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9

2006 1.0k citations D. Gary Gilliland, Scott A. Armstrong et al. profile →
Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1994 933 citations D. Gary Gilliland et al. Cell profile →
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

2002 819 citations Donna Neuberg, D. Gary Gilliland et al. profile →
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

2006 758 citations Ross L. Levine, Martha Wadleigh et al. Blood profile →
Langerhans'-Cell Histiocytosis (Histiocytosis X) -- A Clonal Proliferative Disease

1994 683 citations Cheryl L. Willman, Lambert Busque et al. profile →
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

2009 618 citations D. Gary Gilliland et al. profile →
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.

1995 604 citations Stefan K. Bohlander, D. Gary Gilliland et al. Proceedings of the National Academy of Sciences profile →
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors

2004 513 citations Brian J.P. Huntly, Benjamin H. Lee et al. profile →
Drug therapy for acute myeloid leukemia

2005 512 citations D. Gary Gilliland et al. Blood profile →
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase

2007 336 citations Robert J. Klose, Qin Yan et al. Cell profile →

Peers

Countries citing papers authored by D. Gary Gilliland

Since Specialization

Citations

This map shows the geographic impact of D. Gary Gilliland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Gary Gilliland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Gary Gilliland more than expected).

Fields of papers citing papers by D. Gary Gilliland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Gary Gilliland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Gary Gilliland. The network helps show where D. Gary Gilliland may publish in the future.

Co-authorship network of co-authors of D. Gary Gilliland

This figure shows the co-authorship network connecting the top 25 collaborators of D. Gary Gilliland. A scholar is included among the top collaborators of D. Gary Gilliland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Gary Gilliland. D. Gary Gilliland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Building an Ethical and Trustworthy Biomedical AI Ecosystem for the Translational and Clinical Integration of Foundation Models 2024 ·Bioengineering ·(unknown),D. Gary Gilliland,(unknown),Henning Hermjakob,(unknown),(unknown),(unknown),(unknown),Karol E. Watson,Alex Bui,Wei Wang,Peipei Ping	10
2	Unifying mechanism for different fibrotic diseases 2017 ·Proceedings of the National Academy of Sciences ·Gerlinde Wernig,Shih‐Yu Chen,Lu Cui,(unknown),Jonathan M. Tsai,Neeraja Kambham,Hannes Vogel,Yasodha Natkunam,D. Gary Gilliland,Garry P. Nolan,Irving L. Weissman	145
3	mTOR Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis 2012 ·Cell stem cell ·Demetrios Kalaitzidis,Stephen M. Sykes,Zhu Wang,(unknown),Yuefeng Tang,Christine Ragu,Amit Sinha,Steven Lane,Amanda L. Souza,Clary B. Clish,Dimitrios Anastasiou,D. Gary Gilliland,David T. Scadden,David A. Guertin,Scott A. Armstrong	151
4	Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias 2011 ·Cancer Research ·Brynn T. Kvinlaug,(unknown),Lars Bullinger,Mukundhan Ramaswami,Christopher Sears,(unknown),Stanley E. Lazic,Rachel Okabe,Axel Benner,Benjamin H. Lee,(unknown),Peter J.M. Valk,Ruud Delwel,Scott A. Armstrong,Hartmut Döhner,D. Gary Gilliland,Brian J.P. Huntly	37
5	Akt/foxo signaling pathway enforces the differentiation blockade in myeloid leukemias 2011 ·Experimental Hematology ·Stephen M. Sykes,(unknown),Lars Bullinger,(unknown),Rukh Yusuf,Borja Sáez,Francesca Ferraro,François Mercier,Harprit Singh,Kristina Brumme,Suman Acharya,Claudia Scholl,Zuzana Tóthová,Eyal C. Attar,(unknown),Ronald A. DePinho,D. Gary Gilliland,Scott A. Armstrong,(unknown)	1
6	AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias 2011 ·Cell ·Stephen M. Sykes,Steven Lane,Lars Bullinger,Demetrios Kalaitzidis,Rushdia Z. Yusuf,Borja Sáez,Francesca Ferraro,François Mercier,Harshabad Singh,Kristina Brumme,Sanket S. Acharya,Claudia Scholl,Zuzana Tóthová,Eyal C. Attar,Stefan Fröhling,Ronald A. DePinho,D. Gary Gilliland,Scott A. Armstrong,David T. Scadden	217
7	Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F 2010 ·Clinical Cancer Research ·Windy Berkofsky‐Fessler,Monica Buzzai,(unknown),Steven Fruchtman,Vesna Najfeld,(unknown),Fabrício F. Costa,Jared M. Bischof,Marcelo B. Soares,Melanie J. McConnell,Weijia Zhang,Ross L. Levine,D. Gary Gilliland,Raffaele Calogero,Jonathan D. Licht	30
8	Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia 2010 ·DSpace@MIT (Massachusetts Institute of Technology) ·Michael G. Kharas,Christopher J. Lengner,Fátima Al‐Shahrour,Lars Bullinger,Brian Ball,Samir Zaidi,Kelly Morgan,Winnie F. Tam,Mahnaz Paktinat,Rachel Okabe,Maricel Gozo,William S. Einhorn,Steven Lane,Claudia Scholl,Stefan Fröhling,Mark D. Fleming,Benjamin L. Ebert,D. Gary Gilliland,Rudolf Jaenisch,George Q. Daley	2
9	Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis 2010 ·Haematologica ·Sun Hoe Koo,Brian J.P. Huntly,Yuan Wang,Jessica W. Chen,Kristina Brumme,Brian Ball,Shannon McKinney‐Freeman,Akiko Yabuuchi,Claudia Scholl,(unknown),Leonard I. Zon,Stefan Fröhling,(unknown),D. Gary Gilliland,Thomas Mercher	13
10	Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies 2008 ·Leukemia ·Alfonso Quintás‐Cardama,(unknown),Taghi Manshouri,Francisco Vega,Patrick A. Lennon,Jan Cools,D. Gary Gilliland,(unknown),Jörge E. Cortes,Hagop M. Kantarjian,Guillermo Garcia‐Manero	66
11	The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylasebreakdown → 2007 ·Cell ·Robert J. Klose,Qin Yan,Zuzana Tóthová,Kenichi Yamane,Hediye Erdjument‐Bromage,Paul Tempst,D. Gary Gilliland,Yi Zhang,William G. Kaelin	336
12	Absence of the transcription factor CCAAT enhancer binding protein α results in loss of myeloid identity in bcr/abl-induced malignancy 2006 ·Proceedings of the National Academy of Sciences ·Katharina Wagner,Pu Zhang,Frank Rosenbauer,(unknown),Susumu Kobayashi,Hanna S. Radomska,Jeffery L. Kutok,D. Gary Gilliland,Jürgen Krauter,Daniel G. Tenen	52
13	Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations 2006 ·The Journal of Experimental Medicine ·Hanna S. Radomska,Daniela S. Daniela Sanchez Bassères,Rui Zheng,Pu Zhang,Tajhal Dayaram,Yukiya Yamamoto,David Sternberg,Nathalie A. Lokker,Neill A. Giese,Stefan K. Bohlander,Susanne Schnittger,Marie-Hélène Delmotte,Roger J. Davis,Donald Small,Wolfgang Hiddemann,D. Gary Gilliland,Daniel G. Tenen	161
14	Detection of the <I>FIP1L1-PDGFRA</I> Fusion in Idiopathic Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia 2006 ·Humana Press eBooks ·Jan Cools,Elizabeth H. Stover,D. Gary Gilliland	11
15	Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin 2004 ·Journal of Clinical Investigation ·Jing Chen,Nathan R. Wall,(unknown),Nicole Duclos,Doriano Fabbro,Donna Neuberg,James D. Griffin,Yang Shi,D. Gary Gilliland	52
16	Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML 2004 ·Cancer Research ·Jianming Jiang,J. Guillermo Paez,Jong Suk Lee,Ronghai Bo,Richard M. Stone,(unknown),(unknown),Edward Fox,Ellen Weisberg,James D. Griffin,D. Gary Gilliland,Matthew Meyerson,William R. Sellers	3
17	KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) 2004 ·Leukemia ·Ross L. Levine,Martha Wadleigh,David Sternberg,Iwona Wlodarska,Ilene Galinsky,Richard M. Stone,Daniel J. DeAngelo,D. Gary Gilliland,Jan Cools	46
18	Differentiation block in FLT3 mutant AML by inactivation of C/EBPalpha function by phosphorylation 2003 ·Blood ·Daniela S. Daniela Sanchez Bassères,Hanna S. Radomska,(unknown),David Sternberg,Nathalie A. Lokker,Carol M. Sullivan,(unknown),Susanne Schnittger,Stefan K. Bohlander,Wolfgang Hiddemann,D. Gary Gilliland,Daniel G. Tenen	1
19	Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. 1997 ·PubMed ·Lewis B. Silverman,Thomas W. McLean,Richard D. Gelber,(unknown),D. Gary Gilliland,N.J. Tarbell,Stephen E. Sallan	81
20	An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X 1994 ·Nucleic Acids Research ·Lambert Busque,Jiguang Zhu,(unknown),Barbara Griffith,Cheryl L. Willman,Rona S. Carroll,Peter McL. Black,D. Gary Gilliland	60

About D. Gary Gilliland

D. Gary Gilliland is a scholar working on Hematology, Genetics and Rheumatology, having authored 126 papers that have together received 16.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (48 papers), Chronic Myeloid Leukemia Treatments (47 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (25 papers). The work is most often cited by research in Hematology (8.1k citations), Genetics (4.2k citations) and Rheumatology (2.0k citations). D. Gary Gilliland has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Todd R. Golub, Brian J.P. Huntly, George F. Barker, Michael Lovett, Louise Kelly, Nancy A. Speck, Zuzana Tóthová, Ayalew Tefferi, Jacob M. Rowe and Martin S. Tallman. Their work appears in journals such as Nature, New England Journal of Medicine and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact